Literature DB >> 29940161

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.

Oskar Hansson1, Alvydas Mikulskis2, Anne M Fagan3, Charlotte Teunissen4, Henrik Zetterberg5, Hugo Vanderstichele6, Jose Luis Molinuevo7, Leslie M Shaw8, Manu Vandijck9, Marcel M Verbeek10, Mary Savage11, Niklas Mattsson12, Piotr Lewczuk13, Richard Batrla14, Sandra Rutz15, Robert A Dean16, Kaj Blennow17.   

Abstract

INTRODUCTION: Cerebrospinal fluid (CSF) biomarkers have the potential to improve the diagnostic accuracy of Alzheimer's disease, yet there is a lack of harmonized preanalytical CSF handling protocols.
METHODS: This systematic review summarizes the current literature on the influence of preanalytical variables on CSF biomarker concentration. We evaluated the evidence for three core CSF biomarkers: β-amyloid 42, total tau, and phosphorylated tau.
RESULTS: The clinically important variables with the largest amount of conflicting data included the temperature at which samples are stored, the time nonfrozen samples can be stored, and possible effects of additives such as detergents, blood contamination, and centrifugation. Conversely, we discovered that there is consensus that tube material has a significant effect. DISCUSSION: A unified CSF handling protocol is recommended to reduce preanalytical variability and facilitate comparison of CSF biomarkers across studies and laboratories. In future, experiments should use a gold standard with fresh CSF collected in low binding tubes.
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease diagnosis; Biomarkers; Cerebrospinal fluid; Phosphorylated tau; Preanalytical variables; Total tau; β-Amyloid 42

Mesh:

Substances:

Year:  2018        PMID: 29940161     DOI: 10.1016/j.jalz.2018.05.008

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  36 in total

1.  Characterization of Cerebrospinal Fluid BACE1 Species.

Authors:  Inmaculada Lopez-Font; Claudia P Boix; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2019-07-09       Impact factor: 5.590

2.  Biomarkers of Alzheimer Disease.

Authors:  Melissa M Budelier; Randall J Bateman
Journal:  J Appl Lab Med       Date:  2020-01-01

3.  Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.

Authors:  June Kaplow; Manu Vandijck; Julia Gray; Michio Kanekiyo; Els Huyck; C J Traynham; Rianne Esquivel; Anne M Fagan; Johan Luthman
Journal:  Alzheimers Dement       Date:  2020-01       Impact factor: 21.566

4.  Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Authors:  Sara Hall; Christina D Orrù; Byron Caughey; Oskar Hansson; Geidy E Serrano; Douglas Galasko; Andrew G Hughson; Bradley R Groveman; Charles H Adler; Thomas G Beach
Journal:  Acta Neuropathol Commun       Date:  2022-06-22       Impact factor: 7.578

5.  Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals.

Authors:  Ivan Koychev; Nemanja Vaci; Murat Bilgel; Yang An; Graciela Terrera Muniz; Dean F Wong; John Gallacher; Abhay Mogekhar; Marilyn Albert; Susan M Resnick
Journal:  Alzheimers Dement (Amst)       Date:  2020-03-22

Review 6.  2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  A Leuzy; N J Ashton; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-05       Impact factor: 9.236

7.  Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.

Authors:  Nicholas M Vogt; Jack F V Hunt; Nagesh Adluru; Yue Ma; Carol A Van Hulle; Douglas C Dean Iii; Steven R Kecskemeti; Nathaniel A Chin; Cynthia M Carlsson; Sanjay Asthana; Sterling C Johnson; Gwendlyn Kollmorgen; Richard Batrla; Norbert Wild; Katharina Buck; Henrik Zetterberg; Andrew L Alexander; Kaj Blennow; Barbara B Bendlin
Journal:  Alzheimers Dement       Date:  2021-05-13       Impact factor: 16.655

8.  MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.

Authors:  Donna Wilcock; Gregory Jicha; Deborah Blacker; Marilyn S Albert; Lina M D'Orazio; Fanny M Elahi; Myriam Fornage; Jason D Hinman; Janice Knoefel; Joel Kramer; Richard J Kryscio; Melissa Lamar; Abhay Moghekar; Jillian Prestopnik; John M Ringman; Gary Rosenberg; Abhay Sagare; Claudia L Satizabal; Julie Schneider; Sudha Seshadri; Sandeepa Sur; Russell P Tracy; Sevil Yasar; Victoria Williams; Herpreet Singh; Lidiya Mazina; Karl G Helmer; Roderick A Corriveau; Kristin Schwab; Pia Kivisäkk; Steven M Greenberg
Journal:  Alzheimers Dement       Date:  2021-01-21       Impact factor: 16.655

9.  Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification.

Authors:  Adrienne Elisabeth van der Hoeven; Kevin van Waaij; Denise Bijlenga; Frederik Willem Cornelis Roelandse; Sebastiaan Overeem; Jaap Adriaan Bakker; Rolf Fronczek; Gert Jan Lammers
Journal:  Sleep       Date:  2022-07-11       Impact factor: 6.313

10.  Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.

Authors:  Argonde C van Harten; Heather J Wiste; Stephen D Weigand; Michelle M Mielke; Walter K Kremers; Udo Eichenlaub; Roy B Dyer; Alicia Algeciras-Schimnich; David S Knopman; Clifford R Jack; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2021-07-26       Impact factor: 16.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.